PMCPA Case Library

1,752 PMCPA Rulings.
Every One Analysed.

The only structured, searchable PMCPA case library in the UK. Expert video walkthroughs, podcast episodes, and MCQ assessments on every ruling — so you understand why companies breach the Code, not just that they did.

▶ Video analysis per case
🎧 Podcast per case
✍ MCQ + CPD certificate
🔒 From £299/year
1752+
Case Studies
5 min
Per Video
5 pts
Per Case Passed
8
Themes
📚
Subscribe for full case library access
Read free summaries below, or subscribe to unlock expert video walkthroughs, podcast audio and CPD certificates.
Sign in See plans ↓
Free — Browsing
✓ Browse all 1752+ case titles
✓ Filter by theme & therapy area
✓ See case reference, company & outcome
✗ Search by company or clause
✗ Video walkthroughs
✗ Podcast episodes
✗ MCQ assessments & CPD certificates
Subscribed — Full Access
✓ Search by company, clause & case ref
✓ Expert video walkthrough per case
✓ Podcast episode per case
✓ MCQ quiz — 5 CPD points per pass
✓ Personalised CPD completion certificate
✓ New cases added monthly
Subscribe from £299/year →
Search by company, clause, case reference... 🔒
All (1752) Social Media & Digital (720) HCP Hospitality & Meetings (431) Data & Publications (321) Off-label Promotion (219) Patient Organisations (44) Transfers of Value (9) Promotional Material (4) Samples & Gifts (2)
Therapy Area: All areas Other (360) Oncology (218) Cardiovascular (189) Respiratory (178) CNS & Neurology (169) Infectious Diseases (115) Diabetes (114) Rare Diseases (104) Immunology & Rheumatology (84) Dermatology (67) Obesity & Weight Management (63) Musculoskeletal & Bone (60) Ophthalmology (31)
Showing 39 results · Off-label Promotion · Cardiovascular  · Clear
🔒 Subscribers only
AUTH/3627/4/22
Off-label Promotion Not Upheld 🏥 Cardiovascular ▶ Video 🎙 Podcast
Daiichi Sankyo breached the ABPI Code over Lixiana patient booklets that omitted key bleeding warnin
A health professional complained about two Daiichi Sankyo patient booklets for Lixiana (edoxaban): Understanding your treatment for atrial fibrillation (EDX/21/0229, March 2021) and Understanding y…
Clauses: NONE
2022 🔒 Subscribe
🔒 Subscribers only
AUTH/3633/4/22
Off-label Promotion Not Upheld 🏥 Cardiovascular ▶ Video 🎙 Podcast
Novartis breached the ABPI Code after Entresto HCP website omitted key hepatic/renal safety details
An anonymous cardiac specialist complained about a Novartis UK health professional promotional webpage for Entresto (sacubitril/valsartan): “Starting and monitoring Entresto” (ref 145885, Octob…
Clauses: NONE
2022 🔒 Subscribe
🔒 Subscribers only
AUTH/3649/5/22
Off-label Promotion Not Upheld 🏥 Cardiovascular ▶ Video 🎙 Podcast
Daiichi Sankyo breached Code over SMC summary card
An anonymous health professional complained about a 4-page electronic SMC guidelines summary card for Nilemdo (bempedoic acid) and Nustendi (bempedoic acid/ezetimibe) (Job code BEM/21/0732, prepare…
Clauses: NONE
2022 🔒 Subscribe
🔒 Subscribers only
AUTH/3673/7/22
Off-label Promotion Not Upheld 🏥 Cardiovascular ▶ Video 🎙 Podcast
Daiichi Sankyo press release on Nilemdo/Nustendi
An anonymous, contactable complainant challenged a Daiichi Sankyo UK press release about Nilemdo (bempedoic acid) and Nustendi (bempedoic acid/ezetimibe). The press release (issued to UK journalist…
Clauses: NONE
2022 🔒 Subscribe
🔒 Subscribers only
AUTH/3467/2/21
Off-label Promotion Not Upheld 🏥 Cardiovascular ▶ Video 🎙 Podcast
Anonymous GP v Pfizer
An anonymous, non-contactable complainant describing themself as a GP complained about a named Pfizer representative’s promotion of Eliquis (apixaban), an anticoagulant.The GP alleged the represe…
Clauses: NONE
2021 🔒 Subscribe
🔒 Subscribers only
AUTH/3425/11/20
Off-label Promotion Not Upheld 🏥 Cardiovascular ▶ Video 🎙 Podcast
AUTH/3425/11/20 & AUTH/3426/11/20
The Royal College of General Practitioners (RCGP) Overdiagnosis Group complained about a promotional email for Eliquis (apixaban) (ref PP-ELI-GBR-6974) sent jointly by Pfizer Limited and Bristol-My…
Clauses: NONE
2020 🔒 Subscribe
🔒 Subscribers only
AUTH/3215/6/19
Off-label Promotion Upheld 🏥 Cardiovascular ▶ Video 🎙 Podcast
GP v Pfizer and Bristol-Myers Squibb
A general practitioner complained about a page from a six-page, landscape, gatefold leavepiece promoting Eliquis (apixaban) (ref PP-ELI-GBR-4453) issued by Pfizer Limited and Bristol-Myers Squibb P…
2019 🔒 Subscribe
🔒 Subscribers only
AUTH/3289/12/19
Off-label Promotion Not Upheld 🏥 Cardiovascular ▶ Video 🎙 Podcast
Bristol Myers Squibb and Pfizer
A UK health professional complained about prescribing information (PI) attached to a promotional email for Eliquis (apixaban) received in December 2019.The PI was last revised in July 2019, while t…
Clauses: NONE
2019 🔒 Subscribe
🔒 Subscribers only
AUTH/3035/4/18
Off-label Promotion Upheld 🏥 Cardiovascular ▶ Video 🎙 Podcast
Bayer breached ABPI Code over ambiguous Xarelto renal impairment claim implying use “with confidence
An anonymous UK health professional complained about a Bayer Xarelto (rivaroxaban) advertisement (ref UKXAR01180037d) placed in Pulse, April 2018.Headline claim: “Xarelto Protects Your High-Risk …
Clauses: 4.1,9.1
2018 🔒 Subscribe
🔒 Subscribers only
AUTH/2973/8/17
Off-label Promotion Not Upheld 🏥 Cardiovascular ▶ Video 🎙 Podcast
Bayer
An anonymous, non-contactable complainant alleged a named Bayer representative failed to declare a conflict of interest because her husband was a doctor at a named NHS trust and “gave her access�…
Clauses: NONE
2017 🔒 Subscribe
🔒 Subscribers only
AUTH/2943/3/17
Off-label Promotion Not Upheld 🏥 Cardiovascular ▶ Video 🎙 Podcast
Bayer
An ex-employee of a service provider complained about a named Bayer employee’s conduct during an initial 2017 training course for contract sales representatives on Xarelto.The complaint alleged t…
Clauses: NONE
2017 🔒 Subscribe
🔒 Subscribers only
AUTH/2857/7/16
Off-label Promotion Not Upheld 🏥 Cardiovascular ▶ Video 🎙 Podcast
Daiichi-Sankyo
An anonymous, non-contactable complainant raised four issues about Daiichi-Sankyo UK’s promotional activities and call rates.Allegation 1: market access consultants sent emails to customers (incl…
Clauses: NONE
2016 🔒 Subscribe
🔒 Subscribers only
AUTH/2776/7/15
Off-label Promotion Not Upheld 🏥 Cardiovascular ▶ Video 🎙 Podcast
Bayer
Bristol-Myers Squibb and Pfizer complained about a Xarelto (rivaroxaban) gate-fold leavepiece: “For elderly patients taking aspirin for stroke prevention… It’s time to rethink their protectio…
Clauses: NONE
2015 🔒 Subscribe
🔒 Subscribers only
AUTH/2744/12/14
Off-label Promotion Not Upheld 🏥 Cardiovascular ▶ Video 🎙 Podcast
Aegerion promotional emails about HoFH guidance
A university professor complained about two emails from Aegerion Pharmaceuticals Limited received on 16 and 23 December 2014.Email 1 subject: “New guidance for clinicians on homozygous familial h…
Clauses: NONE
2014 🔒 Subscribe
🔒 Subscribers only
AUTH/2735/9/14
Off-label Promotion Not Upheld 🏥 Cardiovascular ▶ Video 🎙 Podcast
Bayer HealthCare
A doctor in public health complained about an eight-page sponsored supplement: “Venous Thromboembolism – Unblock the System, How to treat DVT in the Community”, sponsored by Bayer HealthCare.…
Clauses: NONE
2014 🔒 Subscribe
🔒 Subscribers only
AUTH/2506/5/12
Off-label Promotion Upheld 🏥 Cardiovascular ▶ Video 🎙 Podcast
AstraZeneca v Eli Lilly and Daiichi-Sankyo
AstraZeneca complained about a four-page Efient (prasugrel) leavepiece (ref UKEFF00714a) issued by Eli Lilly and Company Limited and Daiichi-Sankyo UK Limited.Efient (with acetylsalicylic acid) was…
2012 🔒 Subscribe
🔒 Subscribers only
AUTH/2475/1/12
Off-label Promotion Not Upheld 🏥 Cardiovascular ▶ Video 🎙 Podcast
Johnson & Johnson
Pfizer complained about a six-page gatefold leavepiece for Nicorette Invisi 25mg Patch distributed to prescribers by Johnson & Johnson (ref 06491), used and left with prescribers after a produc…
Clauses: NONE
2012 🔒 Subscribe
🔒 Subscribers only
AUTH/2473/1/12
Off-label Promotion Upheld 🏥 Cardiovascular ▶ Video 🎙 Podcast
Vifor Pharma
Vifor Pharma informed the PMCPA that three advertisements for Ferinject (ferric carboxymaltose) solution for injection/infusion placed by its global colleagues in international journals had not bee…
Clauses: 3.2
2012 🔒 Subscribe
🔒 Subscribers only
AUTH/2537/10/12
Off-label Promotion Not Upheld 🏥 Cardiovascular ▶ Video 🎙 Podcast
Bayer
An anonymous, non-contactable complainant challenged a two-page Bayer HealthCare advertisement for Xarelto (rivaroxaban) published in GP on 24 October 2012 (ref L.GB.09.2012.0568h).The ad, in the c…
Clauses: NONE
2012 🔒 Subscribe
🔒 Subscribers only
AUTH/2437/9/11
Off-label Promotion Not Upheld 🏥 Cardiovascular ▶ Video 🎙 Podcast
Doctor v Boehringer Ingelheim
A medical director at a primary care service provider received a promotional email about Pradaxa (dabigatran) to his NHS email account (email ref DBG 2624).The email was sent via a third-party data…
Clauses: NONE
2011 🔒 Subscribe
🔒 Subscribers only
AUTH/2367/10/10
Off-label Promotion Not Upheld 🏥 Cardiovascular ▶ Video 🎙 Podcast
Takeda misleadingly implied generic losartan was a black triangle medicine in ARB heart
A general practitioner and GP prescribing lead complained about a two-page advertisement for Amias (candesartan) by Takeda in Guidelines in Practice (October 2010).The ad compared candesartan, losa…
Clauses: NONE
2010 🔒 Subscribe
🔒 Subscribers only
AUTH/2300/2/10
Off-label Promotion Not Upheld 🏥 Cardiovascular ▶ Video 🎙 Podcast
AstraZeneca
An ex-employee queried whether prescribing information (PI) in three AstraZeneca advertisements in the BMJ (20 February) was “clear and legible” under the Code.Ads concerned: Seroquel XL (queti…
Clauses: NONE
2010 🔒 Subscribe
🔒 Subscribers only
AUTH/2306/3/10
Off-label Promotion Not Upheld 🏥 Cardiovascular ▶ Video 🎙 Podcast
Pfizer
A pharmacist complained that a Pfizer commercial account manager discussed the price of losartan in early February 2010 when it was not yet available as a generic, and said Pfizer did not yet have …
Clauses: NONE
2010 🔒 Subscribe
🔒 Subscribers only
AUTH/2211/3/09
Off-label Promotion Upheld 🏥 Cardiovascular ▶ Video 🎙 Podcast
Boehringer Ingelheim Limited — Micardis (telmisartan); Micardis Plus (telmisartan/hydrochlorothiazide)
A general practitioner complained about a journal advertisement for Micardis (telmisartan) and Micardis Plus (telmisartan/hydrochlorothiazide) issued by Boehringer Ingelheim Limited, appearing in P…
Clauses: 3.2,7.2,7.4,7.10
2009 🔒 Subscribe
1 2 Next → Page 1 of 2 — 39 cases
Unlock the Full Case Library
Annual subscription — instant access, cancel anytime.
🏆
The only PMCPA case library of its kind
No other provider publishes a structured, searchable library of PMCPA rulings with video and podcast. A single half-day compliance workshop from a specialist provider typically costs £499+ — for one session. Individual access here is £299 for a full year of 2,000+ cases.
PMCPA Case Library — Team (100 seats)
Custom pricing
tailored to your team size
Bulk pricing available — contact us for a quote
Enquire for bulk pricing →
Individual
For a single learner
£299
per year
Less than a single half-day workshop
  • 1 user seat
  • All 1752+ case studies
  • Video + podcast per case
  • MCQ quiz per case
  • 5 points per case passed
  • New cases added monthly
Create account or sign in to buy
Most Popular
Team 5
Up to 5 team members
£999
per year (£200/seat)
£200/person — the most cost-effective team option
  • 5 user seats
  • All case studies included
  • Video, podcast & MCQ per case
  • Team progress dashboard
  • New cases added monthly
  • Admin management portal
Create account or sign in to buy
Team 25+
25+ team members
Custom pricing
tailored to your team size
Bulk pricing available — contact us for a quote
  • 25 user seats
  • All case studies included
  • Video, podcast & MCQ per case
  • Team progress dashboard
  • Bulk seat management
  • Priority support
Enquire for bulk pricing →

Questions? Email [email protected]  ·  14-day money-back guarantee  ·  Annual subscription, auto-renews